Home
Conditions
Carcinoma, Renal Cell

Clinical trial condition

Carcinoma, Renal Cell

Explore clinical trials studying Carcinoma, Renal Cell. Study availability and eligibility vary by location and protocol.

1,363 public trials 252 recruiting studies

Refine in advanced search Browse all conditions

Carcinoma, Renal Cell trial results

Recruiting

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

NCT07397611

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +17 more
Locations: Beth Israel Deaconess Medical Center Boston, Massachusetts, United States

Brigham and Women's Hospital Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Recruiting

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Conditions: Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +31 more
Locations: Tel Aviv Sourasky Medical Center Tel Aviv, Israel

View Trial Details

Recruiting

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

NCT05738694

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations: Cancer Hospital Chinese Academy of Medical Sciences Beijing, China

Peking University First Hospital Beijing, China

Sun Yat-sen University Cancer Center Guangzhou, China

Anhui Provincial Hospital Hefei, China

View Trial Details

Recruiting

Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform

NCT06868927

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations: IRCCS Ospedale San Raffaele Milan, Italia, Italy

View Trial Details

Recruiting

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT07469683

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +16 more
Locations: Severance Hospital Seoul, South Korea

View Trial Details

Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642

Conditions: Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +83 more
Locations: Mayo Clinic in Arizona Phoenix, Arizona, United States

Mayo Clinic in Florida Jacksonville, Florida, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Recruiting

Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis

NCT07461090

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations: Menoufia Faculty of Medicine Shibīn al Kawm, Shebin Elkom, Egypt

View Trial Details

Recruiting

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

NCT04792463

Conditions: Adenocarcinoma, Adenoma, BAP1 Gene Mutation, +41 more
Locations: The Ohio State University Wexner Medical Center Columbus, Ohio, United States

View Trial Details

Recruiting

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

NCT06699602

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites) Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) Commack, New York, United States

View Trial Details

Recruiting

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

NCT07223541

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations: University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States

View Trial Details

Carcinoma, Renal Cell

Carcinoma, Renal Cell trial results

Related conditions